• e-peas

  Participated · Equity · Jul 2026

  Founded in 2014 and headquartered in Louvain-la-Neuve, e-peas develops and markets ultra-low-power semiconductor technology that enables devices to operate from ambient energy sources such as light, RF, vibration, and heat. Its product portfolio includes energy-harvesting power management ICs, microcontrollers, and sensor solutions backed by about 15 years of research and patented IP. The company says its solutions power high-volume applications including solar-powered remote controls, HVAC systems, cameras, and smart tracking devices for global customers. e-peas aims to extend battery lifespans and eliminate battery replacements for industrial and IoT device designers. Financially, the company has raised multiple rounds including €8 million in 2020, €17.5 million in March 2024, and the recent €19.2 million round to support commercial scaling and international expansion. The firm also maintains offices in Switzerland and the USA.

• Synergia Medical

  Participated · Series B · Jan 2023

  Synergia Medical is a preclinical medical device company that has developed NAO.VNS, a non‑metal optoelectronic neurostimulator for vagus nerve stimulation to treat drug‑resistant epilepsy. The company is preparing for First‑In‑Human clinical trials planned for early 2024. It is ISO 13485 certified, operational since 2015, and based in Belgium with a staff of 27 focused on preclinical studies, R&D, quality, and regulatory affairs. Synergia holds a portfolio of nine patents in 15 families and is supported by Wallonia Region grants and the European Innovation Council (Accelerator financing). The team includes co‑founders Attila Borbath (CEO) and Pascal Doguet, and the company has both a business‑oriented Board of Directors and a Scientific Advisory Board of experts in neural stimulation and epilepsy. Financially, the company has previously raised funding and uses the recent proceeds to advance toward clinical milestones. Founded in 2013 by Pascal Doguet and Attila Borbath, Synergia Medical develops opto-electronics medical devices for neurostimulation. Its lead product, NAOS, is a small-form, MRI-safe, implanted neurostimulation device targeting drug-resistant epilepsy with additional therapeutic applications. The company is conducting advanced-stage testing of NAOS ahead of a CE mark filing expected in 2019. Synergia intends to use the funding to complete final testing prior to CE mark submission. The company is also preparing for regulatory approval efforts in the United States where neurostimulation use is increasing. The Series A financing strengthens its position to advance regulatory and commercialization milestones.

• EyeD Pharma

  Participated · Equity · Dec 2021

  EyeD Pharma develops micro‑implants that provide prolonged, controlled release of ophthalmic drugs, with a current focus on treating glaucoma. The company was founded in 2012 and is based in Liège. Its technology platform supports four product candidates, the most advanced being TimoD. EyeD Pharma plans to launch UniD Manufacturing, a CDMO production unit in the Sart‑Tilman science park, in spring 2022 to accelerate product development and manufacturing. The recent financing is intended to fund clinical trials for TimoD and further development of three other candidates. The company has created 93 jobs in the Liège region since 2012 and expects to add about twenty more roles as it scales. EyeD Pharma develops a microscale controlled-release intraocular implant designed to deliver a few nanograms of medication per day for up to three years to treat glaucoma and other eye conditions. The implant is uniquely small (thickness under 1/3 mm) and is placed inside the eye via a brief surgical intervention, aiming to reduce local side effects and improve adherence compared with daily eye drops. The company was founded in 2012 by Professor Jean-Marie Rakic and other ophthalmologists. Since 2018 EyeD Pharma has also been commercializing ophthalmic surgery equipment to bolster financing. Management plans to accelerate development and production of its implants and expand the team. CEO Melanie Mestdagt stated the most advanced project was scheduled to enter the clinical phase in 2020.

• ITeos Therapeutics

  Participated · Series B · Apr 2020

  iTeos Therapeutics develops novel cancer immunotherapies and maintains a pipeline that includes drugs designed to influence the tumor microenvironment. The company is described as a biotech focused on new tumor immune therapies. Its development pipeline specifically includes agents that act on the tumor microenvironment. The article reports that iTeos recently received a strategic investment. The investors named are Boxer Capital and RA Capital Management. The amount of the investment was not disclosed in the article. iTeos Therapeutics is a clinical-stage biotechnology company developing next-generation immunotherapies that target the adenosine pathway and regulatory T cells (Tregs). Its lead programs are EOS-850, an adenosine A2A receptor antagonist in a Phase 1/2 study as a single agent and in combination, and EOS-448, a fully human ADCC‑enabled anti‑TIGIT antibody that entered the clinic. The company plans to initiate dosing for the combination cohorts of the EOS-850 trial in the second quarter of 2020 and recently initiated the Phase 1 portion of the EOS-448 Phase 1/2 study. Proceeds from the financing will support advancement of these clinical programs and additional first‑in‑class preclinical programs targeting the adenosine pathway and Tregs. iTeos is led by President and CEO Michel Detheux and is headquartered in Cambridge, MA with a research center in Gosselies, Belgium. iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on next-generation cancer immunotherapies targeting adenosine and regulatory T cell pathways. Its lead program, EOS-850, is a best-in-class adenosine A2A receptor antagonist currently in a Phase 1b/2a study across four European sites with planned expansion to the United States. A second program, EOS-448, is a fully human ADCC-enabled anti-TIGIT antibody expected to enter Phase 1 in Belgium in early 2020. The company maintains headquarters in Cambridge, MA and a research center in Gosselies, Belgium. iTeos was founded by the Ludwig Institute for Cancer Research and the de Duve Institute. Financially, the company recently received non-dilutive support and has previously completed a $75 million (€64 million) Series B financing in 2018 led by MPM Capital. iTeos Therapeutics develops next-generation cancer immunotherapies with a pipeline focused on modulating the tumor microenvironment. The company plans to move EOS100850, an insurmountable and non‑brain penetrant adenosine A2A receptor antagonist, into the clinic in 2018 and toward clinical proof‑of‑concept, and EOS884448, an anti‑TIGIT antibody, into the clinic in 2019. Its pipeline also includes additional drug candidates targeting the tumor microenvironment. iTeos intends to use the proceeds from the financing to accelerate clinical development of its immuno‑oncology pipeline and to expand into new U.S. offices in Cambridge, Massachusetts. The company is led by CEO Michel Detheux, Ph.D., and was founded out of the Ludwig Institute for Cancer Research and the de Duve Institute in 2011. iTeos Therapeutics develops immuno-oncology drugs, focused on targeting the A2A adenosine receptor, immune checkpoints and non-immunogenic (“cold”) tumors. Its lead candidate is a proprietary A2A antagonist, and the company has a portfolio of additional immuno-oncology programs. iTeos has licensed its IDO1 program, which is in Phase 1 development, to Pfizer. The company uses a platform to identify rational combinations of immunotherapies and novel targets and emphasizes translational tumor immunology and early clinical-trial design. iTeos is based in Gosselies, Belgium and is a spin-off from Ludwig Cancer Research and the de Duve Institute (UCL). The company is supported in part by the Walloon Region and the FEDER. The recent funding will support clinical development activities and advance the launch of a clinical trial.

• Minoryx Therapeutics

  Participated · Series B · Sep 2018

  Minoryx Therapeutics is a clinical-stage biotech developing leriglitazone, a novel brain-penetrant selective PPARγ agonist, for X‑linked adrenoleukodystrophy (X‑ALD) and other CNS diseases. Its lead program, leriglitazone (MIN-102), showed significant clinical benefit in the ADVANCE Phase II/III trial in adult male AMN patients, reducing progression of cerebral lesions and myelopathy symptoms. The company is also running NEXUS, an open-label Phase II/III study in male pediatric patients with early-stage cerebral ALD. Minoryx intends to use the new funding to support the marketing authorization application (MAA) and launch preparations in the EU for adult male X‑ALD patients with AMN and to pursue approval in the US for the same indication. Proceeds will also fund continued development in pediatric cALD and label-expansion efforts into women affected by X‑ALD. The company is led by CEO Marc Martinell and is based in Mataró, Barcelona, Spain, with Belgian facilities. Minoryx Therapeutics is a clinical‑stage biotech focused on new therapies for rare central nervous system (CNS) disorders, with its lead asset leriglitazone (MIN‑102). Leriglitazone is a selective PPARγ agonist being evaluated in three advanced clinical trials: ADVANCE (phase II/III in adrenomyeloneuropathy, AMN), NEXUS (phase II in cerebral adrenoleukodystrophy, cALD) and FRAMES (phase II in Friedreich’s ataxia). The compound has demonstrated brain penetration, a favorable safety profile in phase 1, and preclinical proof‑of‑concept across models of mitochondrial dysfunction, neuroinflammation, demyelination and axonal degeneration. In October 2020 the European Investment Bank approved a €25M venture debt facility to support the development of leriglitazone, provided under the European Fund for Strategic Investments (FEIE). The financing will fund R&D activities targeting orphan genetic CNS diseases and is expected to create more than 50 jobs during implementation. Minoryx was founded in 2011, operates in Spain and Belgium, and to date has raised more than €60M from a consortium of international investors. Minoryx Therapeutics, based in Mataró, Barcelona, is a clinical-stage company focused on therapies for X‑ALD and other rare diseases. Its lead compound, MIN-102, is an orally bioavailable, selective PPAR gamma agonist with a profile suited to CNS-related diseases. MIN-102 is currently in a phase 2/3 clinical trial for adrenomyeloneuropathy (AMN), enrolling adult male patients in Europe and the US, with results expected in 2020. The company intends to use new proceeds to expand the list of indications for MIN-102 and to conduct a new clinical trial for a second orphan CNS indication. Founded in 2011 and led by co-founder and CEO Marc Martinell, Minoryx has raised a total of €50M to date. Khalid Islam serves as chairman of the board. Minoryx Therapeutics, based in Mataró, Barcelona, focuses on discovering new drugs for orphan diseases using its proprietary SEE-Tx platform. Its lead program, MIN-102, is a differentiated PPAR gamma agonist being advanced for multiple CNS indications. The company is exploring MIN-102 for clinical validation in X-ALD, a genetic, progressive neurodegenerative disease with no available pharmacological treatment. Minoryx is also developing a pipeline of non-competitive pharmacological chaperones identified via SEE-Tx. The company intends to use new funds to expand its team, particularly in R&D, and to progress MIN-102 into clinical development. The company is led by CEO and co-founder Marc Martinell. Minoryx focuses on developing therapies for congenital errors of metabolism and other rare or orphan diseases, including a lead program targeting adrenoleukodystrophy (ALD). The company was founded in 2011 and is based at Parc TecnoCampus Mataró‑Maresme. Its lead program is a first drug candidate for ALD; with the new funding the company plans to begin clinical trials. Minoryx closed a €1.6 million financing in early 2015 led by Caixa Capital Risc through the Caixa Innvierte BioMed II fund, with participation from the Swiss Sanfilippo Foundation; that operation also saw the exit of Inveready. The business targets indications for which there are often no approved treatments and is positioning its pipeline toward clinical development.

No current team members are available.